

## MVEC pathway for hepatitis B non-responders ≥ 12-months of age (December 2024)

Age-appropriate hepatitis B vaccine course completed (intramuscular- IM).



Serology ≥ 4 weeks following final dose of IM hepatitis B course shows titre of anti-HBs <10m IU/mL.



Administer 2 dose course of IM Twinrix (720/20) (0 and 6 months)



Serological testing 4 weeks post dose 2 of IM Twinrix (720/20).



Anti-HBs titre ≥10m IU/mL,  
no further action required.



Anti-HBs titre <10m IU/mL



Dose 1 intradermal (ID) hepatitis B immunisation:  
Engerix-B (20 mcg/1.0 mL) 0.25 mL.



Dose 2 ID hepatitis B immunisation  
(2 weeks following dose 1):  
Engerix-B (20 mcg/1.0 mL) 0.25 mL.



Serological testing on same day as dose 2  
of ID immunisation



Anti-HBs titre <10m IU/mL



Anti-HBs titre ≥10m IU/mL,  
no further action required.



Dose 3 ID hepatitis B immunisation  
(2 weeks following dose 2):  
Engerix-B (20 mcg/1.0 mL) 0.25 mL.



Serological testing 4 weeks post dose 3 (final dose)  
of ID hepatitis B immunisation



Anti-HBs titre ≥10m IU/mL  
No further action required



Anti-HBs titre <10m IU/mL

Persistent non-responders should be informed of their immune status and advised on post exposure management: <https://immunisationhandbook.health.gov.au/resources/handbook-tables/table-post-exposure-prophylaxis-for-non-immune-people-exposed-to-a-source>